As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.

Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.

How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.

Bristol Myers Squibb’s Wendy Short Bartie on recasting corporate affairs as an enterprise value engine that connects trust, access and the patient voice.

A new benchmarking survey of 33 biotech and medtech leaders reveals a leadership community operating in crisis mode — and what that means for how the industry needs to rethink peer support, advisory and the isolation built intothe CEO role itself.

The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.

As leaders, we must evaluate solutions to fragmentation by asking the right questions.

Ten life sciences board directors on AI's three hardest questions: developing the next generation of talent, accountability for speed, and board fluency.